Company intelligence / Profile preview

Telios Pharma

Redwood City, California, United Statesorpha.net ↗

Ownership: Private
Employees: ~75
Development stage: Phase 2

Overview

Telios Pharma recently announced successful Phase 2 results for TL-925, a first-in-class topical BTK inhibitor for dry eye disease. The study showed clinically meaningful and statistically significant improvements across multiple signs and symptoms in patients with moderate to severe dry eye disease when dosed twice daily for 28 days. The treatment demonstrated rapid onset of efficacy across multiple ocular regions with favorable safety and tolerability profiles.[2]

Therapeutic areas: EndocrinologyHematologyOtherCardiovascularOphthalmology
Modalities: Small molecule drugsBTK inhibitors
Industry: Biotech

Drug pipeline

2 assets

TL-925

1 more asset in the full pipeline.

Request access →

Partnerships

Kartos Therapeutics, Inc.

Beyond the preview

Go deeper on Telios Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telios Pharma.

Explore the full profile